Dyspepsia dysmotility-like

Observational studies In two identical open studies (El, E2) of oral tegaserod (6 mg bd over 1 year) in 780 women with dysmotility-like functional dyspepsia, who had previously completed two 6-week, randomized, placebo-controlled trials with tegaserod at the same dosage, tegaserod was effective against dyspeptic symptoms. Most adverse events were reported within the first 6 months, and the most common included diarrhea, headache, nausea, abdominal pain, vomiting, and constipation. One patient developed severe bradycardia. 

Chey WD, Howden CW, Tack J, Ligozio G, Earnest DL. Long-term tegaserod treatment lor dysmotility-like functional dyspepsia results of two identical 1-year cohort studies. Dig Dis Sci 2010 55 684-97. 

Placebo-controlled studies The efficacy of tegaserod 6 mg bd for 6 weeks in 2667 women with dysmotility-like functional dyspepsia has been evaluated in two randomized, double-blind, placebo-controlled trials [22 "]. There were some improvements in symptom severity and quality of life in those who took tegaserod, although the clinical implication of these improvements is uncertain. Diarrhea, requiring drug withdrawal, was more common with tegaserod than with placebo. 

Wilmer A, Van Cutsem E, Andrioli A, et al. Ambulatory gastrojejunal manometry in severe motility-like dyspepsia lack of correlation between dysmotility, symptoms and gastric emptying. Gut 1998 42 235-242. 

---